Roberto Iacovelli, Chiara Ciccarese, Giovanni Schinzari, Ernesto Rossi, Brigida Anna Maiorano, Serena Astore, Tatiana D'Angelo, Antonella Cannella, Celeste Pirozzoli, Maria Anna Teberino, Francesco Pierconti, Maurizio Martini, Giampaolo Tortora
Introduction : Prostate cancer (PCa) is one of the most common adult malignancies worldwide, and a major leading cause of cancer-related death in men in Western societies. In the last years, the prognosis of advanced PCa patients has been impressively improved thanks to the development of different therapeutic agents, including taxanes (docetaxel and cabazitaxel), second-generation anti-hormonal agents (abiraterone and enzalutamide), and the radiopharmaceutical Radium-223. However, great efforts are still needed to properly select the most appropriate treatment for each single patient...
February 2020: Expert Review of Molecular Diagnostics